Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24616502 | 0.86 | TSHR (0.43) | CYP3A4ALDH1A1THRBTSHRGLA | |
| SCHEMBL25014091 | 0.81 | CYP3A4 (0.50) | CYP3A4ALDH1A1THRBTSHRGLA | |
| Hydrochloric Acid SCHEMBL25373977 | 0.79 | CYP3A4 (0.48) | CYP3A4ALDH1A1THRBTSHRGLA | |
| SCHEMBL25165270 | 0.78 | POLB (0.36) | CYP3A4ALDH1A1TSHRGLAPOLB | |
| SCHEMBL29295830 | 0.77 | ALOX15 (0.39) | CYP3A4ALDH1A1POLBMAPTCA1 | |
| SCHEMBL23206103 | 0.76 | CYP3A4 (0.43) | CYP3A4ALDH1A1THRBTSHRMAPT | |
| SCHEMBL29676064 | 0.72 | CYP3A4 (0.41) | CYP3A4ALDH1A1THRBTSHRGAA | |
| SCHEMBL21718397 | 0.72 | CYP3A4 (0.41) | CYP3A4ALDH1A1NR1H4THRBTSHR | |
| SCHEMBL25417114 | 0.72 | CYP3A4 (0.41) | CYP3A4ALDH1A1THRBTSHRGAA | |
| SCHEMBL30789287 | 0.72 | THRB (0.39) | CYP3A4ALDH1A1THRBTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | CYP3A4 4444/4885ALDH1A1 3243/4885NR1H4 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.